Drug Profile
Research programme: human embryonic stem cell-derived retinal pigment epithelium therapeutics - Pfizer/UCL
Alternative Names: Human embryonic stem cell derived retinal pigment epithelium living tissue equivalent; Human embryonic stem cell derived RPE living tissue equivalentLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pfizer; University College London
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Age-related macular degeneration
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in United Kingdom (Intraocular, Implant)
- 28 Apr 2009 Preclinical trials in Age-related macular degeneration in United Kingdom (Intraocular)